ArticleNPJ Regenerative medicine2026
A modified bacterial nanocellulose-based advanced therapy product accelerates third-degree burn healing in murine models.
Article in NPJ Regenerative medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe burn injuries represent a major global healthcare burden, with high costs and prolonged hospitalizations. Current treatments, including autologous skin grafting, are limited by donor availability, while allografts carry risks of immune rejection. Advanced Therapy Medicinal Products (ATMPs) offer a promising alternative for skin substitution. We evaluated the efficacy of ARTSkin, an alginate-modified bacterial nanocellulose-based ATMP, in a murine model of third-degree burns. ARTSkin was manufactured under good manufacturing practice (GMP) conditions in two formulations: an acellular scaffold and a cellular construct containing human dermal fibroblasts. The acellular formulation was first assessed in vitro for cytotoxicity and wound-healing capacity using a scratch assay. In vivo, acellular and cellular ARTSkin were evaluated in immunocompetent and immunosuppressed mice, respectively. Acellular ARTSkin was non-cytotoxic and enhanced fibroblast migration and proliferation in vitro. Both formulations significantly improved wound healing in vivo, with accelerated closure and reduced bleeding, hyperemia, edema, and crust formation. Transcriptomic analysis showed that cellular ARTSkin modulated genes involved in the proliferative phase of healing by preventing burn-induced dysregulation of Rac1, Vegfa, and Itga4, and downregulating the profibrotic gene Ctgf. These findings support ARTSkin as a promising skin substitute for burn therapy.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.